We conducted urinary assessments of multiple tubular biomarkers including KIM-1, NGAL, IL-18, MCP-1, clusterin, FABP4, and YKL-40 in ADPKD patients with moderately preserved eGFR who participated in weight loss (IMF or DCR) or metformin safety and feasibility studies. This evidence concerns the gene CLU and autosomal dominant polycystic kidney disease.